PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in...
Read More